Metastatic Cancer Drug Market Size, Share & Growth by 2028

Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), and End User (Hospital, Specialty Clinic, and Others)

  • Report Code : TIPRE00028616
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 233
Buy Now

[Research Report] The metastatic cancer drug market size is projected to reach US$ 68,349.54 million by 2028 from US$ 51,157.97 million in 2021. It is expected to grow at a CAGR of 4.2% from 2021 to 2028.

Metastatic cancer is defined as an advanced stage cancer that spreads to other body parts, and the drugs used for the treatment of advanced-stage cancer are known as metastatic cancer drugs. These drugs are used via various therapies, such as chemotherapy, immunotherapy, and targeted therapy. 

The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing the parameters, such as metastatic cancer drug market size, trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of the globally leading market players.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Metastatic Cancer Drug Market: Strategic Insights

metastatic-cancer-drug-market
Market Size Value inUS$ 51,157.97 Million in 2021
Market Size Value byUS$ 68,349.54 Million by 2028
Growth rateCAGR of 4.2% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The metastatic cancer drug market is attributed to the high prevalence of metastatic cancer and government initiatives to support developments in cancer treatment. However, the high cost of oncology drugs restricts the metastatic cancer drug market growth.

Lucrative Regions in Metastatic Cancer Drug Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights
High Prevalence of Metastatic Cancer

Cancer is one of the health conditions that significantly impact societies worldwide. According to the data provided by the National Institute of Cancer, in 2020, 1,806,590 people were suffering from cancer in the US while 606,520 people died from cancer. According to the American Institute of Cancer Research, in 2020, 18,100 cases were active worldwide. Furthermore, the World Health Organization (WHO) stated that 10,000 deaths, or 1 in 6 deaths globally, were due to cancer. The most common cancer types are lung cancer, breast cancer, colon cancer, rectum cancer, and prostate cancer. The condition develops in 400,000 children every year. Carcinogenic infections—including Helicobacter pylori, hepatitis B virus, human papillomavirus (HPV), hepatitis C virus, and Epstein-Barr virus—caused 13% of cancer cases in 2018, globally. The International Agency for Research on Cancer (IARC) projects that the number of new cancer cases and cancer-related deaths worldwide will grow 1.6–1.7 fold by 2040 to reach 29.5 million and from 16.4 million in 2018. Further, according to the American Society of Clinical Oncology, in 2021, 290,560 people (287,850 women and 2,710 men) in the US were diagnosed with invasive breast cancer. Breast cancer in females has now surpassed lung cancer and is recognized as the most common cancer type worldwide. Approximately, 2,261,419 women were diagnosed with breast cancer in 2020.

Among all the observations recorded about cancer in the US over the past several decades, one statistic has remained unchanged—metastatic cancer accounts for up to 90% of all cancer deaths each year. These numbers have motivated doctors and researchers to find new ways to treat metastasis, which occurs when cancer spreads beyond its point of origin. In the US, 6% of women were diagnosed with metastatic breast cancer in the first diagnosis. Such a rise in the prevalence of metastatic cancer is driving the metastatic cancer drug market growth.

In North America, Canada is expected to witness considerable growth over the forecast period. The main immunotherapy drugs used in Canada are ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), durvalumab (Imfinzi) and atezolizumab (Tecentriq). However, there are other checkpoint inhibitors poised to bring the overall market growth.

Cancer Type-Based Insights

Based on cancer type, the metastatic cancer drug market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. The breast cancer segment accounted for the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period.

Metastatic Cancer Drug Market, by Cancer Type – 2021 and 2028

pharmaceuticals
Metastatic Cancer Drug Market, by Cancer Type – 2021 and 2028
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Route of Administration-Based Insights

Based on route of administration, the metastatic cancer drug market is segmented into intravenous, intramuscular, oral, and others. The intravenous segment accounted for the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.

Drug Class-Based Insights

Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. The PARP inhibitors segment accounted for the largest market share in 2021. However, the HER2 inhibitors segment is expected to register the highest CAGR during the forecast period.

Product-Based Insights

Based on product, the metastatic cancer drug market is bifurcated into branded and generics and biosimilars. The branded segment accounted for a larger market share in 2021. However, the generics and biosimilars segment is estimated to register a higher CAGR during the forecast period.

End User-Based Insights

Based on end user, the metastatic cancer drug market is segmented into hospitals, specialty clinics, and others. The hospital segment accounted for the largest share in 2021, whereas the specialty clinic segment is estimated to register the highest CAGR during the forecast period.

Product launches and approvals are among the commonly adopted strategies by companies to expand their global footprints and product portfolios. The metastatic cancer drug market players also focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. They aim to flourish their market shares with the development of innovative products.

AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; Novartis AG; ASTRAZENECA PLC.; Eli Lilly and Company; MERCK KGaA; and Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc. are the leading companies operating in the metastatic cancer drug market.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Cancer Type, Route of Administration, Drug Class, Product, and End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


Which segment is dominating the metastatic cancer drug market?

The metastatic cancer drug market, by cancer type, is bifurcated into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. The breast cancer segment held the largest share in 2021 and is anticipated to register the highest CAGR during the forecast period.

Who are the major players in market the metastatic cancer drug market?

The metastatic cancer drug market majorly consists of the players such as AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, ASTRAZENECA PLC., Eli Lilly and Company, MERCK KGaA, and Pfizer Inc. (Arena Pharmaceutical GmbH) amongst others.

What are the driving factors for the metastatic cancer drug market across the country?

The factors that are driving and restraining factors that will affect the metastatic cancer drugs market in the coming years. The growth of the market is attributed to some key driving factors such as increasing prevalence of cancer and government initiatives to support drug developments for cancer treatment. However, high cost of oncology drugs is likely to hinder the market growth.

What is the metastatic cancer drug market?

Cancer that spreads from where it started to a distant part of the body is called metastatic cancer. The process by which cancer cells spread to other parts of the body is called metastasis. Metastatic cancer is an advanced cancer stage that spread to the other body parts and the drugs used for the treatment of advanced stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies such as chemotherapy, immunotherapy, and targeted therapy.

The List of Companies - Metastatic Cancer Drug Market

  1. AbbVie Inc.
  2. Amgen Inc.
  3. Bristol-Myers Squibb Company
  4. F. HOFFMANN-LA ROCHE LTD.
  5. Novartis AG
  6. ASTRAZENECA PLC.
  7. Eli Lilly and Company
  8. MERCK KGaA
  9. Pfizer Inc. (Arena Pharmaceutical GmbH)

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Metastatic Cancer Drug Market